KP
Karyopharm Therapeutics Inc.
KPTI · NASDAQ
$1.88 +8.36% (+$0.15)
1M +1.08%
Market Cap $42.6M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.95
49.5% downside
Current Price
$1.88
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KPTI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/S 0.29x
PEG N/A
P/B N/A
Growth
8 /100
Declining Rev. growth 2.39%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 153.28%
Op. margin 56.17%
FCF margin 44.57%
Quality
79 /100
Excellent ROA 201.89%
Asset turnover 1.32x
ROIC 376.87%
Debt
11 /100
High Int. coverage -3.57x
Current ratio 0.79x
Net debt/EBITDA N/A
Stability
55 /100
Moderate Rev. volatility 4.10%
EPS volatility 77.87%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KPTI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Richard A. Paulson
Employees
228
Headquarters
Newton
Upcoming events
02 NOV
Earnings
Upcoming earnings report